tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
tabrecta
novartis biociencias s.a - dicloridrato de capmatinibe monoidratado - antineoplasico
creslip
althaia s.a indústria farmacêutica - rosuvastatina cálcica - antilipemicos
crestor
astrazeneca do brasil ltda - rosuvastatina cálcica - antilipemicos
plenance
libbs farmacÊutica ltda - rosuvastatina cálcica - antilipemicos
rosustatin
nova quimica farmacÊutica s/a - rosuvastatina cálcica - antilipemicos
rosuvastatina calcica
aurobindo pharma indÚstria farmacÊutica limitada - rosuvastatina cálcica - antilipemicos
rosuvastatina calcica
ranbaxy farmacÊutica ltda - rosuvastatina cálcica - antilipemicos
rosuvastatina calcica
sandoz do brasil indÚstria farmacÊutica ltda - rosuvastatina cálcica - antilipemicos
rosuvastatina cálcica
sanofi medley farmacÊutica ltda. - rosuvastatina cálcica - antilipemicos